Phase 3 N=871 Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure — 135; 129; 74 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=458 A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)
Depressive Disorder, Major
Primary: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at the End of Trial — -5; -4.7 Score on a Scale — p=0.6482
Phase 3 N=131 Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction
Breast Cancer · Pain, Postoperative · BRCA1 Mutation
Primary: Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale — 2; 3 score on a scale — p=0.43
Phase 3 N=771 An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
Colitis, Ulcerative
Primary: Percentage of Participants Who Achieved Clinical Remission — 22.5; 31.3 percentage of participants — p=0.0061
Phase 3 N=100 Multicentre Phase III Erythropoietic Protoporphyria Study
Erythropoietic Protoporphyria
Primary: Cumulative Number of Days of Phototoxic Reactions (Study Efficacy Population) — 39; 45; 129; 179 Days
Phase 3 N=104 Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Pancreatectomy for Chronic Pancreatitis
Primary: Percentage of Patients Who Were Insulin Independent After Islet Autotransplantation (IAT) at Day 365±14 Days After Transplant. — 20.0; 21.2 Percentage of participants…
Phase 3 N=838 An Efficacy and Safety Study of Fremanezumab in Adults With Migraine
Migraine Prophylaxis
Primary: DB Period: Change From Baseline in Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Fremanezumab — -0.6; -3.7; -4.1 days/month…
Phase 3 N=84 Prasugrel for Prevention of Early Saphenous Vein Graft Thrombosis
Coronary Artery Bypass
Primary: Prevalence of Intragraft Thrombus at 12-month Follow-up Optical Coherence Tomography Imaging — 14; 14 Participants — p=0.78
Phase 3 N=15,459 Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa
Malaria
Primary: Rate of First or Only Clinical Episode of Plasmodium Falciparum (P. Falciparum) Malaria Infection (CPFMI), or Clinical Malaria Episode of Primary Case Definition…
Phase 3 N=13 Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon
Type 1 Diabetes
Primary: Tmax — 23.8; 15.7 minutes
Phase 3 N=49 A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
Diabetes Type 1
Primary: Rate of Infusion Set Failures — 0.05; 0.03 events per 30 participant days — p=0.375
Phase 3 N=75 A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus
Diabetes Mellitus
Primary: Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia — 100; 100 percentage of participants
Phase 3 N=446 Efficacy and Safety of GSP 301 Nasal Spray in Children (Aged 6 to Under 12 Years) With Seasonal Allergic Rhinitis (SAR)
Seasonal Allergic Rhinitis (SAR)
Primary: Change From Baseline in Average AM and PM Subject-reported 12-hour Reflective Total Nasal Symptom Score ( rTNSS) Over the 14-day Treatment Period — 8.83; 8.84; -2.2…
Phase 3 N=9,901 Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)
Cardiovascular Disease · Diabetes Mellitus, Type 2
Primary: Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal…
Phase 3 N=109 Fluciclovine (18F) PET/CT in biochemicAL reCurrence Of Prostate caNcer
Cancer of the Prostate
Primary: Impact on Patient Treatment /Management — 66; 38; 53; 5 Participants